Substituted pyridazines as skeletal muscle modulators

1. A compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

R 1 is selected from the group consisting of hydrogen, halogen, CN, C 1-6 alkyl, C 1-6 haloalkyl, C(O)OR a , C(O)NR b R c , OR a , NR b R c , C 6-10 aryl and 5-10 membered heteroaryl;

R 2 is selected from the group consisting of C 3-8 cycloalkyl, C 3-8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C 6-10 aryl, 5-10 membered heteroaryl and NR b R c , wherein each of the C 3-8 cycloalkyl, C 3-8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C 6-10 aryl and 5-10 membered heteroaryl groups is optionally substituted with 1, 2, 3, 4 or 5 substituents selected from the group consisting of halogen, CN, oxo, (CH 2 ) n OR a , (CH 2 ) n OC(O)R a , (CH 2 ) n OC(O)OR a , (CH 2 ) n OC(O)NR b R c , (CH 2 ) n NR b R c , (CH 2 ) n NR d C(O)R a , (CH 2 ) n NR d C(O)OR a , (CH 2 ) n NR d C(O)NR b R c , (CH 2 ) n NR d C(O)C(O)NR b R c , (CH 2 ) n NR d C(S)R a , (CH 2 ) n NR d C(S)OR a , (CH 2 ) n NR d C(S)NR b R c , (CH 2 ) n NR d C(NR e )NR b R c , (CH 2 ) n NR d S(O)R a , (CH 2 ) n NR d SO 2 R a , (CH 2 ) n NR d SO 2 NR b R c , (CH 2 ) n C(O)R a , (CH 2 ) n C(O)OR a , (CH 2 ) n C(O)NR b R c , (CH 2 ) n C(S)R a , (CH 2 ) n C(S)OR a , (CH 2 ) n C(S)NR b R c , (CH 2 ) n C(NR e )NR b R c , (CH 2 ) n SR a , (CH 2 ) n S(O)R a , (CH 2 ) n SO 2 R a , (CH 2 ) n SO 2 NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, (CH 2 ) n C 3-8 cycloalkyl, (CH 2 ) n 3-8 membered heterocycloalkyl, (CH 2 ) n C 6-10 aryl and (CH 2 ) n 5-10 membered heteroaryl, wherein each of the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, (CH 2 ) n C 3-8 cycloalkyl, (CH 2 ) n 3-8 membered heterocycloalkyl, (CH 2 ) n C 6-10 aryl and (CH 2 ) n 5-10 membered heteroaryl groups is optionally substituted with 1, 2, 3, 4 or 5 R f substituents;

R 3 is selected from the group consisting of hydrogen, halogen, CN, C 1-6 alkyl, C 1-6 haloalkyl, C(O)OR a , C(O)NR b R c , OR a , NR b R c , C 6-10 aryl and 5-10 membered heteroaryl;

R 4 is selected from the group consisting of hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C(O)R a , C(O)OR a , C(O)NR b R c and SO 2 R a ;

R 5 and R 6 are each independently C 1-6 alkyl;

R 7 is selected from the group consisting of C 3-8 cycloalkyl, C 3-8 cycloalkenyl, 3-8 membered heterocycloalkenyl, C 6-10 aryl and 5-10 membered heteroaryl, each optionally substituted with 1, 2, 3, 4 or 5 substituents selected from the group consisting of halogen, CN, oxo, OR a , OC(O)R a , OC(O)OR a , OC(O)NR b R c , NR b R c , NR d C(O)R a , NR d C(O)OR a , NR d C(O)NR b R c , NR d C(O)C(O)NR b R c , NR d C(S)R a , NR d C(S)OR a , NR d C(S)NR b R c , NR d C(NR e )NR b R c , NR d S(O)R a , NR d SO 2 R a , NR d SO 2 NR b R c , C(O)R a , C(O)OR a , C(O)NR b R c , C(S)R a , C(S)OR a , C(S)NR b R c , C(NR e )NR b R c , SR a , S(O)R a , SO 2 R a , SO 2 NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C 6-10 aryl, C 7-11 aralkyl, and 5-10 membered heteroaryl, wherein each of the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, 3-8 membered heterocycloalkenyl, C 6-10 aryl, C 7-11 aralkyl and 5-10 membered heteroaryl groups is optionally substituted with 1, 2, 3, 4 or 5 R f substituents;

R 8 and R 9 , at each occurrence, are each independently selected from the group consisting of hydrogen, halogen and C 1-6 alkyl;

X is selected from the group consisting of a bond, —(CH 2 ) p —, —(CH 2 ) p C(O)(CH 2 ) q —, —(CH 2 ) p O(CH 2 ) q —, —(CH 2 ) p S(CH 2 ) q —, —(CH 2 ) p NR d (CH 2 ) q —, —(CH 2 ) p C(O)O(CH 2 ) q —, —(CH 2 ) p OC(O)(CH 2 ) q —, —(CH 2 ) p NR d C(O)(CH 2 ) q —, —(CH 2 ) p C(O)NR d (CH 2 ) q —, —(CH 2 ) p NR d C(O)NR d (CH 2 ) q —, —(CH 2 ) p NR d SO 2 (CH 2 ) q —, and —(CH 2 ) p SO 2 NR d (CH 2 ) q —;

R a , at each occurrence, is independently selected from the group consisting of hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C 6-10 aryl, C 7-11 aralkyl and 5-10 membered heteroaryl, wherein each of the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C 6-10 aryl, C 7-11 aralkyl and 5-10 membered heteroaryl groups is optionally substituted with 1, 2, 3, 4 or 5 R f substituents;

R b and R c , at each occurrence, are each independently selected from the group consisting of hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C 6-10 aryl, C 7-11 aralkyl, 5-10 membered heteroaryl, C(O)R g , C(O)OR g , C(O)NR i R j and SO 2 R g , wherein each of the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C 6-10 aryl, C 7-11 aralkyl and 5-10 membered heteroaryl groups is optionally substituted with 1, 2, 3, 4 or 5 R f substituents;

R d , at each occurrence, is independently selected from the group consisting of hydrogen and

C 1-6 alkyl;

R e , at each occurrence, is independently selected from the group consisting of hydrogen, CN, OH, C 1-6 alkoxy, C 1-6 alkyl and C 1-6 haloalkyl;

R f , at each occurrence, is independently selected from the group consisting of halogen, CN, OR h , OC(O)R h , OC(O)OR h , OC(O)NR i R j , NR i R j , NR d C(O)R h , NR d C(O)OR h , NR d C(O)NR i R j , NR d C(O)C(O)NR i R j , NR d C(S)R h , NR d C(S)OR h , NR d C(S)NR i R j , NR d C(NR e )NR i R j , NR d S(O)R h , NR d SO 2 R h , NR d SO 2 NR i R j , C(O)R h , C(O)OR h , C(O)NR i R j , C(S)R h , C(S)OR h , C(S)NR i R j , C(NR e )NR i R j , SR h , S(O)R h , SO 2 R h , SO 2 NR i R j , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C 6-10 aryl, C 7-11 aralkyl and 5-10 membered heteroaryl, wherein each of the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C 6-10 aryl, C 7-11 aralkyl and 5-10 membered heteroaryl groups is optionally substituted with 1, 2, 3, 4 or 5 R k substituents;

or two R f substituents bound to a single carbon atom, together with the carbon atom to which they are both bound, form a group selected from the group consisting of carbonyl, C 3-8 cycloalkyl and 3-8 membered heterocycloalkyl;

R g , at each occurrence, is independently selected from the group consisting of C 1-6 alkyl, C 1-6 haloalkyl, phenyl, naphthyl, and C 7-11 aralkyl, each optionally substituted with 1, 2, 3, 4 or 5 substituents selected from the group consisting of halogen, CN, OH, C 1-6 alkoxy, C 1-6 alkyl and C 1-6 haloalkyl;

R h , at each occurrence, is independently selected from the group consisting of hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C 6-10 aryl, C 7-11 aralkyl and 5-10 membered heteroaryl, wherein each of the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C 6-10 aryl, C 7-11 aralkyl and 5-10 membered heteroaryl groups is optionally substituted with 1, 2, 3, 4 or 5 R k substituents;

R i and R j , at each occurrence, are each independently selected from the group consisting of hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C 6-10 aryl, C 7-11 aralkyl, 5-10 membered heteroaryl, C(O)R g , and C(O)OR g , wherein each of the C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C 6-10 aryl, C 7-11 aralkyl and 5-10 membered heteroaryl groups is optionally substituted with 1, 2, 3, 4 or 5 substituents selected from the group consisting of halogen, CN, OH, C 1-6 alkoxy, C 1-6 alkyl and C 1-6 haloalkyl;

R k , at each occurrence, is independently selected from the group consisting of halogen, CN, OH, C 1-6 alkoxy, NH 2 , NH(C 1-6 alkyl), N(C 1-6 alkyl) 2 , NHC(O)C 1-6 alkyl, NHC(O)C 7-11 aralkyl, NHC(O)OC 1-6 alkyl, NHC(O)OC 7-11 aralkyl, OC(O)C 1-6 alkyl, OC(O)C 7-11 aralkyl, OC(O)OC 1-6 alkyl, OC(O)OC 7-11 aralkyl, C(O)C 1-6 alkyl, C(O)C 7-11 aralkyl, C(O)OC 1-6 alkyl, C(O)OC 7-11 aralkyl, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, and C 2-6 alkynyl, wherein each C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, and C 7-11 aralkyl substituent is optionally substituted with 1, 2 or 3 substituents selected from the group consisting of OH, C 1-6 alkoxy, NH 2 , NH(C 1-6 alkyl), N(C 1-6 alkyl) 2 , NHC(O)C 1-6 alkyl, NHC(O)C 7-11 aralkyl, NHC(O)OC 1-6 alkyl, and NHC(O)OC 7-11 aralkyl;

or two R k substituents bound to a single carbon atom, together with the carbon atom to which they are both bound, form a carbonyl group;

m is 0, 1 or 2;

n, at each occurrence, independently is 0, 1 or 2;

p is 0, 1 or 2; and

q is 0, 1 or 2.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is a bond.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 0.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 1.

5. The compound of claim 4 , or a pharmaceutically acceptable salt thereof, wherein R 8 and R 9 are each hydrogen.

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from the group consisting of hydrogen, halogen, CN, CF 3 and CH 3 .

7. The compound of claim 6 , or a pharmaceutically acceptable salt thereof, wherein R 1 is hydrogen.

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is phenyl optionally substituted with 1, 2, 3, 4 or 5 substituents selected from the group consisting of halogen, CN, (CH 2 ) n OR a , (CH 2 ) n OC(O)R a , (CH 2 ) n OC(O)OR a , (CH 2 ) n OC(O)NR b R c , (CH 2 ) n NR b R c , (CH 2 ) n NR d C(O)R a , (CH 2 ) n NR d C(O)OR a , (CH 2 ) n NR d C(O)NR b R c , (CH 2 ) n NR d C(O)C(O)NR b R c , (CH 2 ) n NR d C(S)R a , (CH 2 ) n NR d C(S)OR a , (CH 2 ) n NR d C(S)NR b R c , (CH 2 ) n NR d C(NR e )NR b R c , (CH 2 ) n NR d S(O)R a , (CH 2 ) n NR d SO 2 R a , (CH 2 ) n NR d SO 2 NR b R c , (CH 2 ) n C(O)R a , (CH 2 ) n C(O)OR a , (CH 2 ) n C(O)NR b R c , (CH 2 ) n C(S)R a , (CH 2 ) n C(S)OR a , (CH 2 ) n C(S)NR b R c , (CH 2 ) n C(NR e )NR b R c , (CH 2 ) n SR a , (CH 2 ) n S(O)R a , (CH 2 ) n SO 2 R a , (CH 2 ) n SO 2 NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, (CH 2 ) n C 3-8 cycloalkyl, (CH 2 ) n 3-8 membered heterocycloalkyl, (CH 2 ) n phenyl, (CH 2 ) n naphthyl and (CH 2 ) n 5-10 membered heteroaryl, wherein each of the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, (CH 2 ) n C 3-8 cycloalkyl, (CH 2 ) n 3-8 membered heterocycloalkyl, (CH 2 ) n phenyl, (CH 2 ) n naphthyl and (CH 2 ) n 5-10 membered heteroaryl groups is optionally substituted with 1, 2, 3, 4 or 5 R f substituents.

9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is 5-10 membered heteroaryl optionally substituted with 1, 2, 3, 4 or 5 substituents selected from the group consisting of halogen, CN, oxo, (CH 2 ) n OR a ,(CH 2 ) n OC(O)R a , (CH 2 ) n OC(O)OR a , (CH 2 ) n OC(O)NR b R c , (CH 2 ) n NR b R c , (CH 2 ) n NR d C(O)R a , (CH 2 ) n NR d C(O)OR a , (CH 2 ) n NR d C(O)NR b R c , (CH 2 ) n NR d C(O)C(O)NR b R c , (CH 2 ) n NR d C(S)R a , (CH 2 ) n NR d C(S)OR a , (CH 2 ) n NR d C(S)NR b R c , (CH 2 ) n NR d C(NR e )NR b R c , (CH 2 ) n NR d S(O)R a , (CH 2 ) n NR d SO 2 R a , (CH 2 ) n NR d SO 2 NR b R c , (CH 2 ) n C(O)R a , (CH 2 ) n C(O)OR a , (CH 2 ) n C(O)NR b R c , (CH 2 ) n C(S)R a , (CH 2 ) n C(S)OR a , (CH 2 ) n C(S)NR b R c , (CH 2 ) n C(NR e )NR b R c , (CH 2 ) n SR a , (CH 2 ) n S(O)R a , (CH 2 ) n SO 2 R a , (CH 2 ) n SO 2 NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, (CH 2 ) n C 3-8 cycloalkyl, (CH 2 ) n 3-8 membered heterocycloalkyl, (CH 2 ) n phenyl, (CH 2 ) n naphthyl and (CH 2 ) n 5-10 membered heteroaryl, wherein each of the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, (CH 2 ) n C 3-8 cycloalkyl, (CH 2 ) n 3-8 membered heterocycloalkyl, (CH 2 ) n phenyl, (CH 2 ) n naphthyl and (CH 2 ) n 5-10 membered heteroaryl groups is optionally substituted with 1, 2, 3, 4 or 5 R f substituents.

10. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein R 2 is selected from the group consisting of indolyl, indazolyl, benzimidazolyl, benzoxazolyl and benzoisoxazolyl, each optionally substituted with 1, 2, 3 or 4 substituents selected from the group consisting of halogen, CN, oxo, (CH 2 ) n OR a , (CH 2 ) n OC(O)R a , (CH 2 ) n OC(O)OR a , (CH 2 ) n OC(O)NR b R c , (CH 2 ) n NR b R c , (CH 2 ) n NR d C(O)R a , (CH 2 ) n NR d C(O)OR a , (CH 2 ) n NR d C(O)NR b R c , (CH 2 ) n NR d C(O)C(O)NR b R c , (CH 2 ) n NR d C(S)R a , (CH 2 ) n NR d C(S)OR a , (CH 2 ) n NR d C(S)NR b R c , (CH 2 ) n NR d C(NR e )NR b R c , (CH 2 ) n NR d S(O)R a , (CH 2 ) n NR d SO 2 R a , (CH 2 ) n NR d SO 2 NR b R c , (CH 2 ) n C(O)R a , (CH 2 ) n C(O)OR a , (CH 2 ) n C(O)NR b R c , (CH 2 ) n C(S)R a , (CH 2 ) n C(S)OR a , (CH 2 ) n C(S)NR b R c , (CH 2 ) n C(NR e )NR b R c , (CH 2 ) n SR a , (CH 2 ) n S(O)R a , (CH 2 ) n SO 2 R a , (CH 2 ) n SO 2 NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, (CH 2 ) n C 3-8 cycloalkyl, (CH 2 ) n 3-8 membered heterocycloalkyl, (CH 2 ) n phenyl, (CH 2 ) n naphthyl and (CH 2 ) n 5-10 membered heteroaryl, wherein each of the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, (CH 2 ) n C 3-8 cycloalkyl, (CH 2 ) n 3-8 membered heterocycloalkyl, (CH 2 ) n phenyl, (CH 2 ) n naphthyl and (CH 2 ) n 5-10 membered heteroaryl groups is optionally substituted with 1, 2, 3, 4 or 5 R f substituents.

11. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein R 2 is selected from the group consisting of pyridyl, pyrimidyl, pyrazyl, pyridazyl, triazyl, furanyl, pyrrolyl, thiophenyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, imidazolyl, triazolyl and tetrazolyl, each optionally substituted with 1, 2, 3 or 4 substituents selected from the group consisting of halogen, CN, oxo, (CH 2 ) n OR a , (CH 2 ) n OC(O)R a , (CH 2 ) n OC(O)OR a , (CH 2 ) n OC(O)NR b R c , (CH 2 ) n NR b R c , (CH 2 ) n NR d C(O)R a , (CH 2 ) n NR d C(O)OR a , (CH 2 ) n NR d C(O)NR b R c , (CH 2 ) n NR d C(O)C(O)NR b R c ,(CH 2 ) n NR d C(S)R a , (CH 2 ) n NR d C(S)OR a , (CH 2 ) n NR d C(S)NR b R c , (CH 2 ) n NR d C(NR e )NR b R c , (CH 2 ) n NR d S(O)R a , (CH 2 ) n NR d SO 2 R a , (CH 2 ) n NR d SO 2 NR b R c , (CH 2 ) n C(O)R a , (CH 2 ) n C(O)OR a , (CH 2 ) n C(O)NR b R c , (CH 2 ) n C(S)R a , (CH 2 ) n C(S)OR a , (CH 2 ) n C(S)NR b R c , (CH 2 ) n C(NR e )NR b R c , (CH 2 ) n SR a , (CH 2 ) n S(O)R a , (CH 2 ) n SO 2 R a , (CH 2 ) n SO 2 NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, (CH 2 ) n C 3-8 cycloalkyl, (CH 2 ) n 3-8 membered heterocycloalkyl, (CH 2 ) n phenyl, (CH 2 ) n naphthyl and (CH 2 ) n 5-10 membered heteroaryl, wherein each of the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, (CH 2 ) n C 3-8 cycloalkyl, (CH 2 ) n 3-8 membered heterocycloalkyl, (CH 2 ) n phenyl, (CH 2 ) n naphthyl and (CH 2 ) n 5-10 membered heteroaryl groups is optionally substituted with 1, 2, 3, 4 or 5 R f substituents.

12. The compound of claim 11 , or a pharmaceutically acceptable salt thereof, wherein R 2 is selected from the group consisting of pyridyl, pyrimidyl, pyrazyl, pyridazyl, triazyl, furanyl, pyrrolyl, thiophenyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, imidazolyl, triazolyl and tetrazolyl, each optionally substituted with a substituent selected from the group consisting of (CH 2 ) n C(O)OR a and (CH 2 ) n C(O)NR b R c ; and optionally substituted with 1, 2 or 3 additional substituents selected from the group consisting of halogen, CN, oxo, (CH 2 ) n OR a , (CH 2 ) n OC(O)R a , (CH 2 ) n OC(O)OR a , (CH 2 ) n OC(O)NR b R c , (CH 2 ) n NR b R c , (CH 2 ) n NR d C(O)R a , (CH 2 ) n NR d C(O)OR a , (CH 2 ) n NR d C(O)NR b R c , (CH 2 ) n NR d C(O)C(O)NR b R c , (CH 2 ) n NR d C(S)R a , (CH 2 ) n NR d C(S)OR a , (CH 2 ) n NR d C(S)NR b R c , (CH 2 ) n NR d C(NR e )NR b R c , (CH 2 ) n NR d S(O)R a , (CH 2 ) n NR d SO 2 R a , (CH 2 ) n NR d SO 2 NR b R c , (CH 2 ) n C(O)R a , (CH 2 ) n C(O)OR a , (CH 2 ) n C(O)NR b R c , (CH 2 ) n C(S)R a , (CH 2 ) n C(S)OR a , (CH 2 ) n C(S)NR b R c , (CH 2 ) n C(NR e )NR b R c , (CH 2 ) n SR a , (CH 2 ) n S(O)R a , (CH 2 ) n SO 2 R a , (CH 2 ) n SO 2 NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, (CH 2 ) n C 3-8 cycloalkyl, (CH 2 ) n 3-8 membered heterocycloalkyl, (CH 2 ) n phenyl, (CH 2 ) n naphthyl and (CH 2 ) n 5-10 membered heteroaryl, wherein each of the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, (CH 2 ) n C 3-8 cycloalkyl, (CH 2 ) n 3-8 membered heterocycloalkyl, (CH 2 ) n phenyl, (CH 2 ) n naphthyl and (CH 2 ) n 5-10 membered heteroaryl groups is optionally substituted with 1, 2, 3, 4 or 5 R f substituents.

13. The compound of claim 11 , or a pharmaceutically acceptable salt thereof, wherein R 2 is selected from the group consisting of pyridyl, pyrimidyl, pyrazyl, pyridazyl, triazyl, furanyl, pyrrolyl, thiophenyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, imidazolyl, triazolyl and tetrazolyl, each optionally substituted with (CH 2 ) n NR d C(O)R a , wherein R a is C 1-6 alkyl or 3-8 membered heterocycloalkyl, each optionally substituted with 1, 2 or 3 additional substituents selected from the group consisting of halogen, CN, oxo, (CH 2 ) n OR a , (CH 2 ) n OC(O)R a , (CH 2 ) n OC(O)OR a , (CH 2 ) n OC(O)NR b R c , (CH 2 ) n NR b R c , (CH 2 ) n NR d C(O)R a , (CH 2 ) n NR d C(O)OR a , (CH 2 ) n NR d C(O)NR b R c , (CH 2 ) n NR d C(O)C(O)NR b R c , (CH 2 ) n NR d C(S)R a , (CH 2 ) n NR d C(S)OR a , (CH 2 ) n NR d C(S)NR b R c , (CH 2 ) n NR d C(NR e )NR b R c , (CH 2 ) n NR d S(O)R a , (CH 2 ) n NR d SO 2 R a , (CH 2 ) n NR d SO 2 NR b R c , (CH 2 ) n C(O)R a , (CH 2 ) n C(O)OR a , (CH 2 ) n C(O)NR b R c , (CH 2 ) n C(S)R a , (CH 2 ) n C(S)OR a , (CH 2 ) n C(S)NR b R c , (CH 2 ) n C(NR e )NR b R c , (CH 2 ) n SR a , (CH 2 ) n S(O)R a , (CH 2 ) n SO 2 R a , (CH 2 ) n SO 2 NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, (CH 2 ) n C 3-8 cycloalkyl, (CH 2 ) n 3-8 membered heterocycloalkyl, (CH 2 ) n phenyl, (CH 2 ) n naphthyl and (CH 2 ) n 5-10 membered heteroaryl, wherein each of the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, (CH 2 ) n C 3-8 cycloalkyl, (CH 2 ) n 3-8 membered heterocycloalkyl, (CH 2 ) n phenyl, (CH 2 ) n naphthyl and (CH 2 ) n 5-10 membered heteroaryl groups is optionally substituted with 1, 2, 3, 4 or 5 R f substituents.

14. The compound of claim 12 , or a pharmaceutically acceptable salt thereof, wherein R 2 is selected from the group consisting of furanyl, pyrrolyl, thiophenyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, imidazolyl, triazolyl and tetrazolyl, each optionally substituted with (CH 2 ) n C(O)NR b R c .

15. The compound of claim 13 , or a pharmaceutically acceptable salt thereof, wherein R 2 is selected from the group consisting of furanyl, pyrrolyl, thiophenyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, imidazolyl, triazolyl and tetrazolyl, each optionally substituted with (CH 2 ) n NR d C(O)R a , wherein R a is selected from the group consisting of C 1-6 alkyl, C 1-6 alkyl-OH and C 1-6 alkyl-NH 2 , each optionally substituted with 1, 2 or 3 additional substituents selected from the group consisting of halogen, CN, (CH 2 ) n OR a , (CH 2 ) n OC(O)R a , (CH 2 ) n OC(O)OR a , (CH 2 ) n OC(O)NR b R c , (CH 2 ) n NR b R c , (CH 2 ) n NR d C(O)R a , (CH 2 ) n NR d C(O)OR a ,(CH 2 ) n NR d C(O)NR b R c , (CH 2 ) n NR d SO 2 R a , (CH 2 ) n NR d SO 2 NR b R c , (CH 2 ) n C(O)R a , (CH 2 ) n C(O)OR a , (CH 2 ) n C(O)NR b R c , (CH 2 ) n SR a , (CH 2 ) n S(O)R a , (CH 2 ) n SO 2 R a , (CH 2 ) n SO 2 NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, (CH 2 ) n C 3-8 cycloalkyl, (CH 2 ) n 3-8 membered heterocycloalkyl, (CH 2 ) n phenyl, (CH 2 ) n naphthyl and (CH 2 ) n 5-10 membered heteroaryl.

16. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is selected from the group consisting of hydrogen, halogen, CN, CF 3 and CH 3 .

17. The compound of claim 16 , or a pharmaceutically acceptable salt thereof, wherein R 3 is hydrogen.

18. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is hydrogen.

19. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 and R 6 are each CH 3 .

20. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 7 is phenyl optionally substituted with 1, 2, 3, 4 or 5 substituents selected from the group consisting of halogen, CN, oxo, OR a , OC(O)R a , OC(O)OR a , OC(O)NR b R c , NR b R c , NR d C(O)R a , NR d C(O)OR a , NR d C(O)NR b R c , NR d C(O)C(O)NR b R c , NR d C(S)R a , NR d C(S)OR a , NR d C(S)NR b R c , NR d C(NR e )NR b R c , NR d S(O)R a , NR d SO 2 R a , NR d SO 2 NR b R c , C(O)R a , C(O)OR a , C(O)NR b R c , C(S)R a , C(S)OR a , C(S)NR b R c , C(NR e )NR b R c , SR a , S(O)R a , SO 2 R a , SO 2 NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C 6-10 aryl, C 7-11 aralkyl, and 5-10 membered heteroaryl,

wherein each of the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, 3-8 membered heterocycloalkenyl, C 6-10 aryl, C 7-11 aralkyl and 5-10 membered heteroaryl groups is optionally substituted with 1, 2, 3, 4 or 5 R f substituents.

21. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 7 is 5-10 membered heteroaryl optionally substituted with 1, 2, 3, 4 or 5 substituents selected from the group consisting of halogen, CN, oxo, OR a , OC(O)R a , OC(O)OR a , OC(O)NR b R c , NR b R c , NR d C(O)R a , NR d C(O)OR a , NR d C(O)NR b R c , NR d C(O)C(O)NR b R c , NR d C(S)R a , NR d C(S)OR a , NR d C(S)NR b R c , NR d C(NR e )NR b R c , NR d S(O)R a , NR d SO 2 R a , NR d SO 2 NR b R c , C(O)R a , C(O)OR a , C(O)NR b R c , C(S)R a , C(S)OR a , C(S)NR b R c , C(NR e )NR b R c , SR a , S(O)R a , SO 2 R a , SO 2 NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C 6-10 aryl, C 7-11 aralkyl, and 5-10 membered heteroaryl,

wherein each of the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, 3-8 membered heterocycloalkenyl, C 6-10 aryl, C 7-11 aralkyl and 5-10 membered heteroaryl groups is optionally substituted with 1, 2, 3, 4 or 5 R f substituents.

22. The compound of claim 21 , or a pharmaceutically acceptable salt thereof, wherein R 7 is pyridyl optionally substituted with 1, 2, 3, 4 or 5 substituents selected from the group consisting of halogen, CN, oxo, OR a , OC(O)R a , OC(O)OR a , OC(O)NR b R c , NR b R c , NR d C(O)R a , NR d C(O)OR a , NR d C(O)NR b R c , NR d C(O)C(O)NR b R c , NR d C(S)R a , NR d C(S)OR a , NR d C(S)NR b R c , NR d C(NR e )NR b R c , NR d S(O)R a , NR d SO 2 R a , NR d SO 2 NR b R c , C(O)R a , C(O)OR a , C(O)NR b R c , C(S)R a , C(S)OR a , C(S)NR b R c , C(NR e )NR b R c , SR a , S(O)R a , SO 2 R a , SO 2 NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, 3-6 membered heterocycloalkyl, 3-6 membered heterocycloalkenyl, phenyl, naphthyl, C 7-11 aralkyl, and 5-10 membered heteroaryl,

wherein each of the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, 3-6 membered heterocycloalkenyl, phenyl, naphthyl, C 7-11 aralkyl and 5-10 membered heteroaryl groups is optionally substituted with 1, 2, 3, 4 or 5 R f substituents.

23. The compound of claim 22 , or a pharmaceutically acceptable salt thereof, wherein R 7 is 2-pyridyl optionally substituted with 1, 2, 3, 4 or 5 substituents selected from the group consisting of halogen, CN, oxo, OR a , OC(O)R a , OC(O)OR a , OC(O)NR b R c , NR b R c , NR d C(O)R a , NR d C(O)OR a , NR d C(O)NR b R c , NR d C(O)C(O)NR b R c , NR d C(S)R a ,NR d C(S)OR a , NR d C(S)NR b R c , NR d C(NR e )NR b R c , NR d S(O)R a , NR d SO 2 R a , NR d SO 2 NR b R c , C(O)R a , C(O)OR a , C(O)NR b R c , C(S)R a , C(S)OR a , C(S)NR b R c , C(NR e )NR b R c , SR a , S(O)R a , SO 2 R a , SO 2 NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, 3-6 membered heterocycloalkyl, 3-6 membered heterocycloalkenyl, phenyl, naphthyl, C 7-11 aralkyl, and 5-10 membered heteroaryl,

wherein each of the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, 3-6 membered heterocycloalkenyl, phenyl, naphthyl, C 7-11 aralkyl and 5-10 membered heteroaryl groups is optionally substituted with 1, 2, 3, 4 or 5 R f substituents.

24. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein;

m is 0;

R 2 is selected from the group consisting of phenyl and 5-10 membered heteroaryl optionally substituted with 1, 2, 3, 4 or 5 substituents selected from the group consisting of halogen, CN, oxo, (CH 2 ) n OR a , (CH 2 ) n NR b R c , (CH 2 ) n NR d C(O)R a , (CH 2 ) n NR d C(O)OR a , (CH 2 ) n NR d C(O)NR b R c , (CH 2 ) n NR d S(O)R a , (CH 2 ) n NR d SO 2 R a , (CH 2 ) n NR d SO 2 NR b R c , (CH 2 ) n C(O)R a , (CH 2 ) n C(O)OR a , (CH 2 ) n C(O)NR b R c , (CH 2 ) n SO 2 R a , (CH 2 ) n SO 2 NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, and C 2-6 alkenyl, wherein each of the C 1-6 alkyl, and C 2-6 alkenyl groups is optionally substituted with 1, 2, 3, 4 or 5 R f substituents;

R 4 is hydrogen;

R 5 is CH 3 ;

R 6 is CH 3 ; and

R 7 is selected from the group consisting of phenyl and pyridyl, each optionally substituted with 1, 2 or 3 substituents selected from the group consisting of halogen, CN, OR a , C 1-6 alkyl, and C 1-6 haloalkyl.

25. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

m is 1;

R 2 is selected from the group consisting of phenyl and 5-10 membered heteroaryl optionally substituted with 1, 2, 3, 4 or 5 substituents selected from halogen, CN, oxo, (CH 2 ) n OR a , (CH 2 ) n NR b R c , (CH 2 ) n NR d C(O)R a , (CH 2 ) n NR d C(O)OR a , (CH 2 ) n NR d C(O)NR b R c , (CH 2 ) n NR d S(O)R a , (CH 2 ) n NR d SO 2 R a , (CH 2 ) n NR d SO 2 NR b R c , (CH 2 ) n C(O)R a , (CH 2 ) n C(O)OR a , (CH 2 ) n C(O)NR b R c , (CH 2 ) n SO 2 R a , (CH 2 ) n SO 2 NR b R c , C 1-6 alkyl, C 1-6 haloalkyl, and C 2-6 alkenyl, wherein each of the C 1-6 alkyl, and C 2-6 alkenyl groups is optionally substituted with 1, 2, 3, 4 or 5 R f substituents;

R 4 is hydrogen;

R 5 is CH 3 ;

R 6 is CH 3 ;

R 7 is selected from the group consisting of phenyl and pyridyl, each optionally substituted with 1, 2 or 3 substituents selected from the group consisting of halogen, CN, OR a , C 1-6 alkyl, and C 1-6 haloalkyl;

R 8 is hydrogen; and

R 9 is hydrogen.

26. The compound of claim 1 , selected from the group consisting of

3-{6-[(1-methyl-1-phenylethyl)amino]pyridazin-3-yl}benzamide;

3-{6-[(1-methyl-1-phenylethyl)amino]pyridazin-3-yl}benzenecarbonitrile;

3-{6-[(1-methyl-1-(2-pyridyl)ethyl)amino]pyridazin-3-yl}benzamide;

4-{6-[(1-methyl-1-phenylethyl)amino]pyridazin-3-yl}benzamide;

(6-(1H-indazol-5-yl)pyridazin-3-yl)(1-methyl-1-phenylethyl)amine;

[6-(6-amino(3-pyridyl))pyridazin-3-yl](1-methyl-1-phenylethyl)amine;

(1-methyl-1-phenylethyl)(6-phenylpyridazin-3-yl)amine;

3-(6-{[1-(4-fluorophenyl)-isopropyl]amino}pyridazin-3-yl)benzamide;

3-(6-{[1-(3-fluorophenyl)-isopropyl]amino}pyridazin-3-yl)benzamide;

4-fluoro-3-(6-{[1-(4-fluorophenyl)-isopropyl]amino}pyridazin-3-yl)benzamide;

3-(6-{[1-(3-chloro(2-pyridyl))-isopropyl]amino}pyridazin-3-yl)-4-fluorobenzamide;

4-fluoro-3-(6-{[1-methyl-1-(6-oxo(2-hydropyridyl))ethyl]amino}pyridazin-3-yl)benzamide;

3-[6-({1-[6-(difluoromethoxy)(2-pyridyl)]-isopropyl}amino)pyridazin-3-yl]-4-fluorobenzamide;

3-[6-({1-[6-(difluoromethoxy)(2-pyridyl)]-isopropyl}amino)pyridazin-3-yl]benzamide;

{3-[6-({1-[6-(difluoromethoxy)(2-pyridyl)]-isopropyl}amino)pyridazin-3-yl]phenyl}(methylsulfonyl)amine;

2-[6-({1-[6-(difluoromethoxy)(2-pyridyl)]-isopropyl}amino)pyridazin-3-yl]-1,3-thiazole-5-carboxamide;

4-fluoro-3-(6-{[1-(3-fluoro(2-pyridyl))-isopropyl]amino}pyridazin-3-yl)benzamide;

2-(6-{[1-(3-chloro(2-pyridyl))-isopropyl]amino}pyridazin-3-yl)-1,3-thiazole-5-carboxamide;

6-(6-{[1-(3-chloro(2-pyridyl))-isopropyl]amino}pyridazin-3-yl)imidazo[2,1-b]1,3-thiazoline-3-carboxamide; and

2-[2-(6-{[1-(3-chloro(2-pyridyl))-isopropyl]amino}pyridazin-3-yl)-1,3-thiazol-5-yl]acetamide;

or a pharmaceutically acceptable salt thereof.

27. The compound of claim 1 , selected from the group consisting of

3-{6-[(1-methyl-1-phenylethyl)amino]pyridazin-3-yl}benzamide;

3-{6-[(1-methyl-1-phenylethyl)amino]pyridazin-3-yl}benzenecarbonitrile;

3-{6-[(1-methyl-1-(2-pyridyl)ethyl)amino]pyridazin-3-yl}benzamide;

4-{6-[(1-methyl-1-phenylethyl)amino]pyridazin-3-yl}benzamide;

(6-(1H-indazol-5-yl)pyridazin-3-yl)(1-methyl-1-phenylethyl)amine;

[6-(6-amino(3-pyridyl))pyridazin-3-yl](1-methyl-1-phenylethyl)amine;

(1-methyl-1-phenylethyl)(6-phenylpyridazin-3-yl)amine;

3-(6-{[1-(4-fluorophenyl)-isopropyl]amino}pyridazin-3-yl)benzamide;

3-(6-{[1-(3-fluorophenyl)-isopropyl]amino}pyridazin-3-yl)benzamide;

4-fluoro-3-(6-{[1-(4-fluorophenyl)-isopropyl]amino}pyridazin-3-yl)benzamide; and

3-(6-{[1-(3-chloro(2-pyridyl))-isopropyl]amino}pyridazin-3-yl)-4-fluorobenzamide;

or a pharmaceutically acceptable salt thereof.

28. The compound of claim 1 , selected from the group consisting of:

3-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)benzamide;

4-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)benzamide;

5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)pyridine-3-carbonitrile;

methyl 5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)pyridine-3-carboxylate;

5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)pyridine-3-carboxamide;

[2-(4-fluorophenyl)-2-methylpropyl](6-pyrazol-4-ylpyridazin-3-yl)amine;

3-(6-{[2-(2-chlorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)benzamide;

3-(6-{[2-(4-chlorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)benzamide;

3-(6-{[2-(2,4-difluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)benzamide;

(6-(1H-indazol-6-yl)pyridazin-3-yl)[2-(4-fluorophenyl)-2-methylpropyl]amine;

3-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)benzenecarbonitrile;

(6-(1H-indazol-5-yl)pyridazin-3-yl)[2-(4-fluorophenyl)-2-methylpropyl]amine;

3-(6-{[2-(2-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)benzamide;

(6-(1H-indazol-4-yl)pyridazin-3-yl)[2-(4-fluorophenyl)-2-methylpropyl]amine;

5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-3-hydrobenzimidazol-2-one;

3-(6-{[2-(3-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)benzamide;

(6-(1H-1,2,3,4-tetraazol-5-yl)pyridazin-3-yl)[2-(4-fluorophenyl)-2-methylpropyl]amine;

5-(6-{[2-(2-chlorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)pyridine-3-carboxamide;

5-(6-{[2-(2-chlorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)pyridine-3-carbonitrile;

[6-(3-amino(1H-indazol-5-yl))pyridazin-3-yl][2-(4-fluorophenyl)-2-methylpropyl]amine;

[6-(3-amino(1H-indazol-7-yl))pyridazin-3-yl][2-(4-fluorophenyl)-2-methylpropyl]amine;

[6-(3-aminobenzo[3,4-d]isoxazol-5-yl)pyridazin-3-yl][2-(4-fluorophenyl)-2-methylpropyl]amine;

[6-(3-aminobenzo[d]isoxazol-7-yl)pyridazin-3-yl][2-(4-fluorophenyl)-2-methylpropyl]amine;

[2-(2-chlorophenyl)-2-methylpropyl](6-(3-pyridyl)pyridazin-3-yl)amine;

[2-(2-chlorophenyl)-2-methylpropyl](6-pyrimidin-5-ylpyridazin-3-yl)amine;

3-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}-5-methylpyridazin-3-yl)benzenecarbonitrile;

3-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}-5-methyl pyridazin-3-yl)benzamide;

3-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}-4-methylpyridazin-3-yl)benzenecarbonitrile;

3-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}-4-methylpyridazin-3-yl)benzamide;

[3-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)phenyl]-N-(2-hydroxyethyl)carboxamide;

N-(2,3-dihydroxypropyl)[3-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)phenyl]carboxamide;

3-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)phenyl piperidyl ketone;

3-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)phenyl morpholin-4-yl ketone;

N-(2-aminoethyl)[3-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)phenyl]carboxamide;

tert-butyl 4-{[3-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)phenyl]carbonyl}piperazinecarboxylate;

2-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)benzamide;

[2-(4-fluorophenyl)-2-methylpropyl][6-(1-methyl(1H-indazol-6-yl))pyridazin-3-yl]amine;

3-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)phenyl piperazinyl ketone;

[6-(3-amino-1-methyl(1H-indazol-5-yl))pyridazin-3-yl][2-(4-fluorophenyl)-2-methylpropyl]amine;

5-(6-{[2-(2-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-3-hydrobenzimidazol-2-one;

[6-(3-amino(1H-indazol-6-yl))pyridazin-3-yl][2-(4-fluorophenyl)-2-methylpropyl]amine;

[6-(3-aminobenzo[d]isoxazol-6-yl)pyridazin-3-yl][2-(4-fluorophenyl)-2-methylpropyl]amine;

3-fluoro-5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)benzamide;

3-(5-cyano-6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)benzamide;

6-(3-carbamoylphenyl)-3-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazine-4-carboxamide;

5-[6-({2-[2-(hydroxymethyl)phenyl]-2-methylpropyl}amino)pyridazin-3-yl]-3-hydrobenzimidazol-2-one;

5-{6-[(2-methyl-2-phenylpropyl)amino]pyridazin-3-yl}-3-hydrobenzimidazol-2-one;

N-{3-[(tert-butoxy)carbonylamino]propyl}[3-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)phenyl]carboxamide;

N-(3-aminopropyl)[3-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)phenyl]carboxamide;

(6-benzimidazol-5-ylpyridazin-3-yl)[2-(4-fluorophenyl)-2-methylpropyl]amine;

[2-(4-fluorophenyl)-2-methylpropyl][6-(2-methylbenzimidazol-5-yl)pyridazin-3-yl]amine;

[6-(2-aminobenzimidazol-5-yl)pyridazin-3-yl][2-(4-fluorophenyl)-2-methylpropyl]amine;

[3-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)phenyl]-N-methylcarboxamide;

N-[5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-2-pyridyl]acetamide;

[2-(4-fluorophenyl)-2-methylpropyl][6-(2-methylbenzoxazol-5-yl)pyridazin-3-yl]amine;

[2-(4-fluorophenyl)-2-methylpropyl][6-(2-methylbenzoxazol-6-yl)pyridazin-3-yl]amine;

3-(6-{[2-(3-fluoro(2-pyridyl))-2-methylpropyl]amino}pyridazin-3-yl)benzamide;

3-(6-{[2-(5-fluoro(2-pyridyl))-2-methylpropyl]amino}pyridazin-3-yl)benzamide;

6-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-3-hydrobenzoxazol-2-one;

3-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)phenyl phenyl ketone;

4-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)phenyl phenyl ketone;

[2-(4-fluorophenyl)-2-methylpropyl][6-(3-iodo(1H-indazol-5-yl))pyridazin-3-yl]amine;

[2-(4-fluorophenyl)-2-methylpropyl](6-(4-1,2,5,6-tetrahydropyridyl)pyridazin-3-yl)amine;

[2-(4-fluorophenyl)-2-methylpropyl](6-pyrazol-3-ylpyridazin-3-yl)amine;

1-acetyl-4-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-1,2,5,6-tetrahydropyridine;

methyl 4-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-1,2,5,6-tetrahydropyridinecarboxylate;

4-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-1-(methylsulfonyl)-1,2,5,6-tetrahydropyridine;

4-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-1,2,5,6-tetrahydropyridinecarboxamide;

(tert-butoxy)-N-(2-{[5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)(1H-indazol-3-yl)]amino}ethyl)carboxamide;

[2-(4-fluorophenyl)-2-methylpropyl](6-pyrrolo[3,2-b]pyridin-6-ylpyridazin-3-yl)amine;

[2-(4-fluorophenyl)-2-methylpropyl](6-pyrazolo[5,4-b]pyridin-5-ylpyridazin-3-yl)amine;

5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-3-hydrobenzoxazol-2-one;

(6-{3-[(2-aminoethyl)amino](1H-indazol-5-yl)}pyridazin-3-yl)[2-(4-fluorophenyl)-2-methylpropyl]amine;

4-fluoro-3-(6-{[2-(4-fluorophenyl)-2-methyl propyl]amino}pyridazin-3-yl)benzamide;

[2-(4-fluorophenyl)-2-methylpropyl][6-(3-methyl(1H-indazol-6-yl))pyridazin-3-yl]amine;

[6-(3-amino(1H-indazol-5-yl))pyridazin-3-yl][2-methyl-2-(2-methylphenyl)propyl]amine;

5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-1H-indazole-3-carbonitrile;

5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-1H-indazole-3-carboxamide;

[4-(2-{[6-(3-amino(1H-indazol-5-yl))pyridazin-3-yl]amino}-tert-butyl)phenyl]methan-1-ol;

{[4-(2-{[6-(3-amino(1H-indazol-5-yl))pyridazin-3-yl]amino}-tert-butyl)phenyl]methyl}dimethylamine;

[2-(4-fluorophenyl)-2-methylpropyl][6-(3-vinyl(1H-indazol-5-yl))pyridazin-3-yl]amine;

[6-(3-ethyl(1H-indazol-5-yl))pyridazin-3-yl][2-(4-fluorophenyl)-2-methylpropyl]amine;

3-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-1,2,4-oxadiazole-5-carboxamide;

[6-(3-amino(1H-indazol-6-yl))pyridazin-3-yl][2-(3-fluoro(2-pyridyl))-2-methylpropyl]amine;

[6-(3-amino(1H-indazol-5-yl))pyridazin-3-yl][2-(5-fluoro(2-pyridyl))-2-methylpropyl]amine;

[6-(3-amino(1H-indazol-6-yl))pyridazin-3-yl][2-(5-fluoro(2-pyridyl))-2-methylpropyl]amine;

1-[5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-1H-indazol-3-yl]ethane-1,2-diol;

2-amino-6-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-3-hydropyrimidin-4-one;

N-[6-(2-amino-6-oxohydropyrimidin-4-yl)pyridazin-3-yl](tert-butoxy)-N-[2-(4-fluorophenyl)-2-methylpropyl]carboxamide;

6-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-3-hydroquinazolin-4-one;

[6-(3-amino(1H-indazol-5-yl))pyridazin-3-yl](2-methyl-2-(1,3-oxazol-2-yl)propyl)amine;

ethyl 2-fluoro-5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)benzoate;

2-amino-6-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-3-hydroquinazolin-4-one;

4-(2-{[6-(3-amino(1H-indazol-5-yl))pyridazin-3-yl]amino}-tert-butyl)benzenecarbonitrile;

4-(2-{[6-(3-amino(1H-indazol-5-yl))pyridazin-3-yl]amino}-tert-butyl)benzamide;

[6-(3-amino(1H-indazol-5-yl))pyridazin-3-yl]{2-[4-(aminomethyl)phenyl]-2-methylpropyl}amine;

5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-1H-indazole-3-carboxamidine;

2-[4-(2-{[6-(3-amino(1H-indazol-5-yl))pyridazin-3-yl]amino}-tert-butyl)phenyl]propan-2-ol;

[3-(2-{[6-(3-amino(1H-indazol-5-yl))pyridazin-3-yl]amino}-tert-butyl)phenyl]methan-1-ol;

2-[5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-1H-indazol-3-yl]propan-2-ol;

3-(6-{[2-(3,5-difluoro(2-pyridyl))-2-methylpropyl]amino}pyridazin-3-yl)benzamide;

[5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-1H-indazol-3-yl]methan-1-ol;

{[3-(2-{[6-(3-amino(1H-indazol-5-yl))pyridazin-3-yl]amino}-tert-butyl)phenyl]methyl}dimethylamine;

3-(2-{[6-(3-amino(1H-indazol-5-yl))pyridazin-3-yl]amino}-tert-butyl)benzenecarbonitrile;

3-(2-{[6-(3-amino(1H-indazol-5-yl))pyridazin-3-yl]amino}-tert-butyl)benzamide;

2-[3-(2-{[6-(3-amino(1H-indazol-5-yl))pyridazin-3-yl]amino}-tert-butyl)phenyl]propan-2-ol;

[6-(3-amino(1H-indazol-5-yl))pyridazin-3-yl][2-(3,5-difluoro(2-pyridyl))-2-methylpropyl]amine;

N-[5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-1H-indazol-3-yl]acetamide;

[6-(3-aminopyrazolo[5,4-b]pyridin-5-yl)pyridazin-3-yl][2-(4-fluorophenyl)-2-methylpropyl]amine;

[3-(2-{[6-(3-amino(1H-indazol-5-yl))pyridazin-3-yl]amino}-tert-butyl)phenyl]-N-methylcarboxamide;

[3-(2-{[6-(3-amino(1H-indazol-5-yl))pyridazin-3-yl]amino}-tert-butyl)phenyl]-N,N-dimethylcarboxamide;

[5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)(1H-indazol-3-yl)](methylsulfonyl)amine;

[2-(2-{[6-(3-amino(1H-indazol-5-yl))pyridazin-3-yl]amino}-tert-butyl)phenyl]methan-1-ol;

[6-(3-amino(1H-indazol-5-yl))pyridazin-3-yl]{2-[3-(aminomethyl)phenyl]-2-methylpropyl}amine;

5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-1H-indazole-7-carboxamide;

[6-(3-amino(1H-indazol-5-yl))pyridazin-3-yl][2-(3-methoxyphenyl)-2-methylpropyl]amine;

[6-(3-amino(1H-indazol-5-yl))pyridazin-3-yl][2-methyl-2-(4-methylphenyl)propyl]amine;

2-[3-(2-{[6-(3-amino(1H-indazol-5-yl))pyridazin-3-yl]amino}-tert-butyl)phenyl]ethan-1-ol;

(6-(1H-indazol-5-yl)pyridazin-3-yl)[2-(3-fluoro(2-pyridyl))-2-methylpropyl]amine;

N-[6-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)benzimidazol-2-yl]acetamide;

6-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-1,3-dihydroquinazoline-2,4-dione;

2-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)pyridine-4-carboxamide;

6-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)pyridine-2-carboxamide;

3-(6-{(tert-butoxy)-N-[2-(4-fluorophenyl)-2-methyl propyl]carbonylamino}pyridazin-3-yl)benzamide;

3-(6-{(tert-butoxy)-N-[2-(4-fluorophenyl)-2-methylpropyl]carbonylamino}pyridazin-3-yl)-4-fluorobenzamide;

2-fluoro-4-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)benzoic acid;

methyl 3-amino-5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-1H-indazolecarboxylate;

methyl 5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-3-(methoxycarbonylamino)-1H-indazolecarboxylate;

N-[5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)(1H-indazol-3-yl)]methoxycarboxamide;

[3-amino-5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)(1H-indazolyl)]-N,N-dimethylcarboxamide;

6-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-3,3-dimethylindolin-2-one;

2-amino-7-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-3-hydroquinazolin-4-one;

3-{6-[(2-methyl-2-pyrimidin-2-ylpropyl)amino]pyridazin-3-yl}benzamide;

[2-(4-fluorophenyl)-2-methylpropyl](6-{3-[(methylethyl)amino](1H-indazol-5-yl)}pyridazin-3-yl)amine;

[6-(2-aminopyrimidin-5-yl)pyridazin-3-yl][2-(4-fluorophenyl)-2-methylpropyl]amine;

[2-(4-fluorophenyl)-2-methylpropyl]{6-[3-(methylamino)(1H-indazol-5-yl)]pyridazin-3-yl}amine;

[2-(4-fluorophenyl)-2-methylpropyl][6-(2-methoxypyrimidin-5-yl)pyridazin-3-yl]amine;

[2-(4-fluorophenyl)-2-methylpropyl][6-(2-methoxy(3-pyridyl))pyridazin-3-yl]amine;

{6-[3-(ethylamino)(1H-indazol-5-yl)]pyridazin-3-yl}[2-(4-fluorophenyl)-2-methylpropyl]amine;

[2-(4-fluorophenyl)-2-methylpropyl](6-phenylpyridazin-3-yl)amine;

5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)hydropyridin-2-one;

[6-(2-amino(4-pyridyl))pyridazin-3-yl][2-(4-fluorophenyl)-2-methylpropyl]amine;

[6-(4-aminophenyl)pyridazin-3-yl][2-(4-fluorophenyl)-2-methylpropyl]amine;

[6-(3-aminophenyl)pyridazin-3-yl][2-(4-fluorophenyl)-2-methylpropyl]amine;

3-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)pyridin-2-ol;

5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-3-hydropyrimidin-2-one;

5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-1,3,4-oxadiazolin-2-one;

[6-(6-amino(3-pyridyl))pyridazin-3-yl][2-(4-fluorophenyl)-2-methylpropyl]amine;

[6-(5-aminopyrazol-3-yl)pyridazin-3-yl][2-(4-fluorophenyl)-2-methylpropyl]amine;

[2-(4-fluorophenyl)-2-methylpropyl][6-(6-methoxy(2-pyridyl))pyridazin-3-yl]amine;

N-[4-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)imidazol-2-yl]acetamide;

5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)pyridine-2-carbonitrile;

[6-(2-aminoimidazol-4-yl)pyridazin-3-yl][2-(4-fluorophenyl)-2-methylpropyl]amine;

5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)pyridine-2-carboxamide;

6-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)pyridin-2-ol;

{6-[6-(aminomethyl)(3-pyridyl)]pyridazin-3-yl}[2-(4-fluorophenyl)-2-methylpropyl]amine;

[2-(4-fluorophenyl)-2-methylpropyl][6-(2-fluorophenyl)pyridazin-3-yl]amine;

[2-(4-fluorophenyl)-2-methylpropyl][6-(3-fluorophenyl)pyridazin-3-yl]amine;

[2-(4-fluorophenyl)-2-methylpropyl][6-(4-fluorophenyl)pyridazin-3-yl]amine;

[6-(2-chlorophenyl)pyridazin-3-yl][2-(4-fluorophenyl)-2-methylpropyl]amine;

[6-(3-chlorophenyl)pyridazin-3-yl][2-(4-fluorophenyl)-2-methylpropyl]amine;

[6-(4-chlorophenyl)pyridazin-3-yl][2-(4-fluorophenyl)-2-methylpropyl]amine;

4-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)benzenecarbonitrile;

[2-(4-fluorophenyl)-2-methylpropyl](6-(3-pyridyl)pyridazin-3-yl)amine;

[6-(6-amino(2-pyridyl))pyridazin-3-yl][2-(4-fluorophenyl)-2-methylpropyl]amine;

N-{[5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-2-pyridyl]methyl}acetamide;

N-{[5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)(2-pyridyl)]methyl}methoxycarboxamide;

[2-(4-fluorophenyl)-2-methylpropyl](6-(2-pyridyl)pyridazin-3-yl)amine;

6-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)pyridine-3-carboxamide;

[3-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)phenyl]methan-1-ol;

(tert-butoxy)-N-{[3-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)phenyl]methyl}carboxamide;

{6-[3-(aminomethyl)phenyl]pyridazin-3-yl}[2-(4-fluorophenyl)-2-methylpropyl]amine;

[2-(4-fluorophenyl)-2-methylpropyl][6-(5-methoxy(2-pyridyl))pyridazin-3-yl]amine;

6-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)pyridin-3-ol;

[2-(4-fluorophenyl)-2-methylpropyl](6-{3-[(2,2,2-trifluoroethyl)amino](1H-indazol-5-yl)}pyridazin-3-yl)amine;

[5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)(1H-indazol-3-yl)]dimethylamine;

[2-(4-fluorophenyl)-2-methylpropyl][6-(3-{[2-(phenylmethoxy)ethyl]amino}(1H-indazol-5-yl))pyridazin-3-yl]amine;

2-{[5-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-1H-indazol-3-yl]amino}ethan-1-ol;

2-(6-{[2-(3-fluoro(2-pyridyl))-2-methylpropyl]amino}pyridazin-3-yl)-1,3-thiazole-5-carboxamide;

[6-(3-(2H-1,2,3,4-tetraazol-5-yl)phenyl)pyridazin-3-yl][2-(3-fluoro(2-pyridyl))-2-methylpropyl]amine;

2-[2-(6-{[1-(3-fluoro(2-pyridyl))-isopropyl]amino}pyridazin-3-yl)-1,3-thiazol-5-yl]acetamide;

(2S)-N-[[2-[6-[[2-(3-fluoro-2-pyridinyl)-2-methylpropyl]amino]-3-pyridazinyl]-5-thiazolyl]methyl]-2-pyrrolidinecarboxamide;

3-(6-{[2-(3-chloro(2-pyridyl))-2-methylpropyl]amino}pyridazin-3-yl)benzamide;

3-(6-{[2-(3-chloro(2-pyridyl))-2-methylpropyl]amino}pyridazin-3-yl)-4-fluorobenzamide;

3-(6-{[2-(3-chloro(2-pyridyl))-2-methylpropyl]amino}pyridazin-3-yl)benzenecarbonitrile;

3-(6-{[2-(3-chloro(2-pyridyl))-2-methylpropyl]amino}pyridazin-3-yl)-4-fluorobenzenecarbonitrile;

2-[2-(6-{[2-(3-chloro(2-pyridyl))-2-methylpropyl]amino}pyridazin-3-yl)-1,3-thiazol-5-yl]acetamide;

2-amino-N-{[2-(6-{[2-(3-chloro(2-pyridyl))-2-methylpropyl]amino}pyridazin-3-yl)(1,3-thiazol-5-yl)]methyl}-2-methylpropanamide;

6-(6-{[2-(3-chloro(2-pyridyl))-2-methylpropyl]amino}pyridazin-3-yl)imidazo[2,1-b]1,3-thiazoline-3-carboxamide;

(tert-butoxy)-N-[6-(2,3-dioxo(1,4-dihydroquinoxalin-6-yl))pyridazin-3-yl]-N-[2-(4-fluorophenyl)-2-methylpropyl]carboxamide;

{2-[3-(2-{[6-(3-amino(1H-indazol-5-yl))pyridazin-3-yl]amino}-tert-butyl)phenyl]ethyl}dimethylamine;

3-(2-{[6-(3-amino(1H-indazol-5-yl))pyridazin-3-yl]amino}-tert-butyl)phenol;

6-(6-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyridazin-3-yl)-1,4-dihydroquinoxaline-2,3-dione;

[6-(3-amino(1H-indazol-5-yl))pyridazin-3-yl]{2-[2-(methoxymethyl)phenyl]-2-methylpropyl}amine;

3-(6-{(tert-butoxy)-N-[2-(3-fluoro(2-pyridyl))-2-methylpropyl]carbonylamino}pyridazin-3-yl)benzamide;

(tert-butoxy)-N-[2-(3-fluoro(2-pyridyl))-2-methylpropyl]-N-[6-(2-hydroxybenzimidazol-5-yl)pyridazin-3-yl]carboxamide;

5-(6-{[2-(3-fluoro(2-pyridyl))-2-methylpropyl]amino}pyridazin-3-yl)benzimidazol-2-ol; and

[6-(3-amino(1H-indazol-5-yl))pyridazin-3-yl][2-(3-fluoro(2-pyridyl))-2-methylpropyl]amine,

or a pharmaceutically acceptable salt thereof.

29. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

30. The pharmaceutical composition of claim 29 , wherein the pharmaceutical composition is formulated for oral, sublingual, subcutaneous, parenteral, intravenous, intranasal, topical, transdermal, intraperitoneal, intramuscular, intrapulmonary, vaginal, rectal, or intraocular administration.

31. The pharmaceutical composition of claim 30 , wherein the pharmaceutical composition is formulated for oral administration.

32. A method for modulating skeletal muscle contractility in a patient comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

33. The method of claim 32 , wherein the patient suffers from a disease or condition selected from the group consisting of neuromuscular disorders, conditions of muscle wasting, muscular myopathies, rehabilitation-related deficits, peripheral vascular disease, peripheral arterial disease, frailty, muscle atrophy, muscle fatigue, metabolic syndrome, chronic fatigue syndrome, and obesity.

34. The method of claim 32 , wherein the patient suffers from a disease selected from the group consisting of amyotrophic lateral sclerosis, spinal muscular atrophy and myasthenia gravis.

35. The method of claim 32 , wherein the patient suffers from a disease selected from the group consisting of peripheral vascular disease and peripheral arterial disease.